

ASX Appendix 4D

Half-Year Financial Report to 31 December 2013

1. Details of reporting period

Name of Entity	Cynata Therapeutics Limited
ABN	98 104 037 372
Period Ended	31 December 2013
Previous Corresponding Period	31 December 2012

2. Results for announcement to the market

				\$
Revenues from ordinary activities	Down	7%	to	49,686
Loss for the half-year	Up	354%	to	1,727,561
Total comprehensive loss for the half-year attributable to members	Down	353%	to	1,723,583
		Amount Per Security		Franked Amount Per Security
Final Dividend		Nil		Nil
Interim Dividend		Nil		Nil
Previous Corresponding Period		Nil		Nil
Record Date for Determining Entitlements	Not Applicable			

Brief explanation of any of the figures reported above necessary to enable figures to be understood:

For further information, refer to the review of operations contained in the directors' report, which forms part of the attached consolidated financial statements.

3. Net tangible asset backing

	31 December 2013	31 December 2012
Net tangible backing per ordinary security	11.01 cents	0.42 cents

4. Details of entities over which control has been gained or lost during the period

On 24 September 2013, Cynata Therapeutics Limited exercised its option to acquire all remaining shares in Cynata Inc, increasing its interest in Cynata Inc from 33% to 100%. The acquisition became effective as from 1 December 2013. The purchase of the remaining 67% of the share capital of Cynata Inc was satisfied by the issue of 10,000,001 shares at an issue price of \$0.40 each. No cash payment was made for the 67% interest.

5. Details of Dividends

No dividend has been paid or recommended to be paid for the half-year ended 31 December 2013.

6. Details of dividend reinvestment plans

N/A

7 Details of associate and joint venture entities

N/A

8. Foreign entities

N/A

9. Audit

This report has been based on accounts that have been subject to an audit review. There are no items of dispute with the auditor and the audit review is not subject to qualification.



Dr Ross Macdonald
Managing Director/CEO

27 February 2014